Shots:

• The P-III (FRESCO-2) trial evaluating fruquintinib + BSC vs PBO + BSC in patients with metastatic CRC who had progressed on standard CT and relevant biologic agents & had progressed on, or were intolerant to TAS-102 & regorafenib at the US, EU, Japan & Australia
• The trial met its 1EPs of OS & also showed an improvement in PFS. The safety profile was consistent with prior reported studies. The results will be submitted at an upcoming medical meeting
• The company will discuss the results with the agencies in the US, EU, and Japan & plans to submit fruquintinib’s MAA shortly. The company also retains all commercial rights to fruquintinib outside of China & was marketed under the brand name Elunate

Ref: GlobeNewswire | Image: HUTCHMED